Literature DB >> 19160253

Combined psychotherapy plus benzodiazepines for panic disorder.

Norio Watanabe1, Rachel Churchill, Toshi A Furukawa.   

Abstract

BACKGROUND: The efficacy of combining psychotherapy and benzodiazepines for panic disorder is unclear, despite widespread use.
OBJECTIVES: To examine the efficacy of the combination compared with either treatment alone. SEARCH STRATEGY: Randomised trials comparing the combination of psychotherapy and benzodiazepine with either therapy alone for panic disorder were identified. The Cochrane Depression, Anxiety and Neurosis Group Studies and References Registers were searched. References of relevant trials and other reviews were checked. Experts in the field were contacted. Additional unpublished data were sought from authors of the original trials. SELECTION CRITERIA: Two authors independently checked the records retrieved by the searches to identify randomised trials comparing the combined therapy versus either of the monotherapies, among adults with panic disorder. DATA COLLECTION AND ANALYSIS: Two authors independently checked eligibility, assessed quality and extracted data from the eligible trials using a standardised data extraction form. The primary outcome was "response" based on global judgement. Random-effects meta-analyses were conducted, combining data from included trials. MAIN
RESULTS: Three trials met eligibility criteria. A 16-week behaviour therapy intervention was used in two trials, and a 12-week cognitive-behaviour therapy intervention in the third. Duration of follow-up varied, ranging from 0 to 12 months. Two trials (total 166 participants) provided data comparing combination with psychotherapy alone (both using behaviour therapy). No statistically significant differences were observed in response during the intervention (relative risk (RR) for combination 1.25, 95% CI 0.78 to 2.03, P = 0.35), at the end of the intervention (RR 0.78, 0.45 to 1.35, P = 0.37), or at the last follow-up time point, although the follow-up data suggested that the combination might be inferior to behaviour therapy alone (RR 0.62, 0.36 to 1.07, P = 0.08). One trial (77 participants) compared combination with a benzodiazepine alone. No differences were found in response during the intervention (RR 1.57, 0.83 to 2.98, P = 0.17). Although the combination appeared to be superior to the benzodiazepine alone at the end of treatment (RR 3.39, 1.03 to 11.21, P = 0.05) the finding was only borderline statistically significant, and no significant differences were observed at the 7-month follow-up (RR 2.31, 0.79 to 6.74, P = 0.12). AUTHORS'
CONCLUSIONS: The review established the paucity of high quality evidence investigating the efficacy of psychotherapy combined with benzodiazepines for panic disorder. Currently, there is inadequate evidence to assess the clinical effects of psychotherapy combined with benzodiazepines for patients who are diagnosed with panic disorder.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19160253     DOI: 10.1002/14651858.CD005335.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  15 in total

1.  Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting.

Authors:  Devin Tucker; Kanna Hayashi; M-J Milloy; Seonaid Nolan; Huiru Dong; Thomas Kerr; Evan Wood
Journal:  Addict Behav       Date:  2015-10-09       Impact factor: 3.913

Review 2.  Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults.

Authors:  Hui Li; Jijun Wang; Chunbo Li; Zeping Xiao
Journal:  Cochrane Database Syst Rev       Date:  2014-09-17

3.  Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.

Authors:  Michael W Otto; R Kathryn McHugh; Kathleen M Kantak
Journal:  Clin Psychol (New York)       Date:  2010-06-08

Review 4.  Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions.

Authors:  Kenneth E Freedland; David C Mohr; Karina W Davidson; Joseph E Schwartz
Journal:  Psychosom Med       Date:  2011-05-02       Impact factor: 4.312

Review 5.  Emerging drugs for the treatment of anxiety.

Authors:  James W Murrough; Sahab Yaqubi; Sehrish Sayed; Dennis S Charney
Journal:  Expert Opin Emerg Drugs       Date:  2015-06-01       Impact factor: 4.191

Review 6.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

7.  [Tree decision analysis of the therapeutic alternatives for Panic Disorders in Primary Care].

Authors:  Fernando Navarro-Mateu; Ascensión Garriga-Puerto; Juan Antonio Sánchez-Sánchez
Journal:  Aten Primaria       Date:  2009-07-24       Impact factor: 1.137

8.  Benzodiazepines versus placebo for panic disorder in adults.

Authors:  Johanna Breilmann; Francesca Girlanda; Giuseppe Guaiana; Corrado Barbui; Andrea Cipriani; Mariasole Castellazzi; Irene Bighelli; Simon Jc Davies; Toshi A Furukawa; Markus Koesters
Journal:  Cochrane Database Syst Rev       Date:  2019-03-28

Review 9.  Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis.

Authors:  Alessandro Pompoli; Toshi A Furukawa; Hissei Imai; Aran Tajika; Orestis Efthimiou; Georgia Salanti
Journal:  Cochrane Database Syst Rev       Date:  2016-04-13

10.  Different Attitudes of Patients and Psychiatrists Toward Benzodiazepine Treatment.

Authors:  Yasushi Kawamata; Norio Sugawara; Masamichi Ishioka; Kazutoshi Kubo; Katsuji Suzuki; Akira Fujii; Hanako Furukori; Taku Nakagami; Norio Yasui-Furukori; Kazutaka Shimoda
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.